BBK Healthcare, Inc. Evolves to Become BBK Worldwide
BBK Adds Global Alliances and Restructures Offerings to Advance Patient Recruitment.
BOSTON-BBK Healthcare, Inc., a leading patient recruitment company for the clinical R&D segment of the pharmaceutical, biotechnology, and medical device industries announces the evolution of its global capabilities and presence to become BBK Worldwide. The company is leveraging its 20-year industry experience in patient recruitment planning and implementation in North America with wider global coverage and a strategic restructuring of offerings to respond to the increasingly complex needs of clinical research sponsors entering new and emerging global markets.
BBK Worldwide's official launch coincides with the Drug Information Association (DIA) Annual Meeting in Philadelphia from June 18–22, where BBK will convene global alliance members for an inaugural summit meeting prior to the DIA conference.
Geographic expansion includes BBK Worldwide offices in London and Prague, and the addition of the BBK Worldwide Alliance, a network of select, best-in-class companies with capabilities in more than 75 countries.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
